&nbsp;

iccu-thumbnail-CancerPoster_FIRSTNATIONS_EN.jpg

Mar 2022

Document

iccu-thumbnail-OH-CancerPoster_INUIT.jpg

Mar 2022

Document

iccu-thumbnail-OH-CancerPoster_METIS.jpg

Mar 2022

Regimen

CAPE

Cancer Type:

Gastrointestinal,

Hepatobiliary / Liver / Bile Duct

Intent: Adjuvant

Funding:

ODB - General Benefit

capecitabine

Drugs Used:

capecitabine

Quick Link(s):

Regimen Monograph

Jul 2024

Regimen

HYPERCVAD+PEG

Cancer Type:

Hematologic,

Leukemia - Acute Lymphoblastic (ALL)

Intent: Curative

Funding:

ODB - General Benefit

dexamethasone

New Drug Funding Program

Pegaspargase (Outpatient) - Adult Acute Lymphoblastic Leukemia (ALL) Lymphoblastic Lymphoma Mixed or Biphenotypic Leukemia

Drugs Used:

Quick Link(s):

Regimen Monograph

Apr 2022

Regimen

CRBPPACL(W)+PEMB

Cancer Type:

Breast

Intent: Neoadjuvant

Funding:

New Drug Funding Program

Pembrolizumab - Previously Untreated High-Risk Early-Stage Triple Negative Breast Cancer

Drugs Used:

Quick Link(s):

Regimen Monograph

Sep 2023

Regimen

AC+PEMB

Cancer Type:

Breast

Intent: Neoadjuvant

Funding:

New Drug Funding Program

Pembrolizumab - Previously Untreated High-Risk Early-Stage Triple Negative Breast Cancer

Drugs Used:

Quick Link(s):

Regimen Monograph

Sep 2023

Regimen

PEMB

Cancer Type:

Breast

Intent: Adjuvant

Funding:

New Drug Funding Program

Pembrolizumab - Previously Untreated High-Risk Early-Stage Triple Negative Breast Cancer

Drugs Used:

pembrolizumab

Quick Link(s):

Regimen Monograph

Feb 2023

Regimen

CARFDEXA+ISAT; CARFDEXA(W)+ISAT

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

ODB - General Benefit

dexamethasone

New Drug Funding Program

Isatuximab and Carfilzomib - In Combination with Dexamethasone for Relapsed or Refractory Multiple Myeloma

New Drug Funding Program

Isatuximab and Carfilzomib - In Combination with Dexamethasone for Relapsed or Refractory Multiple Myeloma

Drugs Used:

Quick Link(s):

Regimen Monograph

Feb 2024

Regimen

ASCI

Cancer Type:

Hematologic,

Leukemia - Chronic Myeloid (CML)

Intent: Palliative

Funding:

Exceptional Access Program

asciminib - For the treatment of Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, according to clinical criteria

Drugs Used:

asciminib

Quick Link(s):

Regimen Monograph

Jun 2023

Regimen

VEMU+RITU

Cancer Type:

Hematologic,

Leukemia - Hairy Cell

Intent: Palliative

Drugs Used:

vemURAFenib (Unfunded),

riTUXimab (Unfunded)

Quick Link(s):

Regimen Monograph

Mar 2022

Document